| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sjogren's Syndrome | 29 | 2020 | 35 | 5.440 |
Why?
|
| Head and Neck Neoplasms | 18 | 2022 | 118 | 4.500 |
Why?
|
| Mouth Diseases | 16 | 2020 | 21 | 4.350 |
Why?
|
| Lichen Planus, Oral | 7 | 2022 | 11 | 3.120 |
Why?
|
| Xerostomia | 16 | 2022 | 30 | 2.460 |
Why?
|
| Stomatitis | 15 | 2021 | 17 | 2.240 |
Why?
|
| Tooth Extraction | 16 | 2015 | 18 | 1.930 |
Why?
|
| Neoplasms | 20 | 2021 | 621 | 1.880 |
Why?
|
| Quality of Life | 19 | 2022 | 828 | 1.760 |
Why?
|
| Dental Caries | 10 | 2022 | 20 | 1.730 |
Why?
|
| Humans | 135 | 2022 | 29449 | 1.640 |
Why?
|
| Antibiotic Prophylaxis | 13 | 2015 | 29 | 1.540 |
Why?
|
| Bacteremia | 11 | 2015 | 53 | 1.430 |
Why?
|
| Mycoses | 3 | 2020 | 13 | 1.410 |
Why?
|
| Mouth Mucosa | 11 | 2019 | 29 | 1.390 |
Why?
|
| Dental Care for Chronically Ill | 8 | 2017 | 9 | 1.380 |
Why?
|
| Lupus Erythematosus, Systemic | 8 | 2017 | 145 | 1.350 |
Why?
|
| Dental Care | 10 | 2021 | 18 | 1.250 |
Why?
|
| Oral Hemorrhage | 8 | 2013 | 8 | 1.130 |
Why?
|
| Candidiasis, Oral | 4 | 2016 | 10 | 1.120 |
Why?
|
| Postoperative Hemorrhage | 9 | 2013 | 38 | 1.100 |
Why?
|
| Female | 66 | 2022 | 18341 | 1.070 |
Why?
|
| Mouth | 8 | 2017 | 22 | 1.050 |
Why?
|
| Practice Guidelines as Topic | 13 | 2021 | 375 | 0.970 |
Why?
|
| Middle Aged | 43 | 2022 | 10920 | 0.970 |
Why?
|
| Facial Pain | 3 | 2013 | 21 | 0.920 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2013 | 71 | 0.910 |
Why?
|
| Male | 56 | 2022 | 17969 | 0.900 |
Why?
|
| Osteoradionecrosis | 4 | 2021 | 5 | 0.900 |
Why?
|
| Gingival Recession | 2 | 2022 | 2 | 0.890 |
Why?
|
| Burning Mouth Syndrome | 3 | 2013 | 4 | 0.880 |
Why?
|
| Antineoplastic Agents | 12 | 2019 | 547 | 0.840 |
Why?
|
| Toothbrushing | 4 | 2015 | 4 | 0.830 |
Why?
|
| Tongue Diseases | 2 | 2020 | 4 | 0.820 |
Why?
|
| Steroids | 2 | 2020 | 36 | 0.820 |
Why?
|
| Clobetasol | 1 | 2022 | 25 | 0.810 |
Why?
|
| Oral Health | 4 | 2018 | 29 | 0.790 |
Why?
|
| Endocarditis, Bacterial | 5 | 2015 | 9 | 0.780 |
Why?
|
| Immunosuppressive Agents | 4 | 2013 | 167 | 0.740 |
Why?
|
| Antifungal Agents | 3 | 2018 | 34 | 0.720 |
Why?
|
| Oral Medicine | 4 | 2015 | 4 | 0.720 |
Why?
|
| Temporomandibular Joint Disorders | 3 | 2013 | 4 | 0.710 |
Why?
|
| Tooth Diseases | 4 | 2010 | 6 | 0.680 |
Why?
|
| Retrospective Studies | 19 | 2021 | 3135 | 0.680 |
Why?
|
| Glucocorticoids | 2 | 2022 | 149 | 0.680 |
Why?
|
| Prospective Studies | 13 | 2022 | 2041 | 0.680 |
Why?
|
| Adult | 35 | 2020 | 8511 | 0.670 |
Why?
|
| Salivary Glands, Minor | 5 | 2019 | 9 | 0.660 |
Why?
|
| Prosthesis-Related Infections | 2 | 2015 | 23 | 0.650 |
Why?
|
| Aspirin | 3 | 2010 | 66 | 0.630 |
Why?
|
| Stomatognathic Diseases | 1 | 2017 | 5 | 0.630 |
Why?
|
| Mouth Neoplasms | 1 | 2018 | 15 | 0.620 |
Why?
|
| Graft vs Host Disease | 2 | 2014 | 18 | 0.580 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2021 | 83 | 0.560 |
Why?
|
| Alu Elements | 1 | 2016 | 1 | 0.560 |
Why?
|
| Administration, Topical | 5 | 2022 | 130 | 0.550 |
Why?
|
| Autoimmune Diseases | 4 | 2020 | 50 | 0.540 |
Why?
|
| Salivary Gland Diseases | 5 | 2021 | 5 | 0.540 |
Why?
|
| Salivation | 4 | 2016 | 5 | 0.540 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2013 | 85 | 0.520 |
Why?
|
| Radiotherapy | 7 | 2019 | 75 | 0.490 |
Why?
|
| Arthritis, Rheumatoid | 5 | 2017 | 33 | 0.490 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2017 | 143 | 0.490 |
Why?
|
| Oral Surgical Procedures | 5 | 2013 | 7 | 0.470 |
Why?
|
| Medical Oncology | 3 | 2021 | 74 | 0.470 |
Why?
|
| Periodontal Diseases | 7 | 2020 | 13 | 0.470 |
Why?
|
| Toothache | 3 | 2013 | 7 | 0.450 |
Why?
|
| Risk Factors | 18 | 2020 | 3596 | 0.450 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 57 | 0.440 |
Why?
|
| Microarray Analysis | 2 | 2013 | 19 | 0.440 |
Why?
|
| Oral Submucous Fibrosis | 1 | 2012 | 1 | 0.430 |
Why?
|
| Cytokines | 4 | 2016 | 243 | 0.430 |
Why?
|
| Dental Service, Hospital | 2 | 2011 | 2 | 0.420 |
Why?
|
| Biopsy, Needle | 1 | 2011 | 90 | 0.390 |
Why?
|
| Professional Practice | 1 | 2011 | 23 | 0.390 |
Why?
|
| Anti-Bacterial Agents | 5 | 2012 | 286 | 0.390 |
Why?
|
| Gastrointestinal Diseases | 3 | 2020 | 38 | 0.390 |
Why?
|
| Cohort Studies | 10 | 2022 | 1701 | 0.390 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2021 | 401 | 0.380 |
Why?
|
| Diagnosis, Differential | 4 | 2014 | 493 | 0.380 |
Why?
|
| Oral Hygiene | 6 | 2017 | 15 | 0.360 |
Why?
|
| Incidence | 8 | 2019 | 1126 | 0.360 |
Why?
|
| International Normalized Ratio | 2 | 2012 | 5 | 0.350 |
Why?
|
| Mucositis | 2 | 2006 | 8 | 0.350 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2011 | 173 | 0.350 |
Why?
|
| Time Factors | 9 | 2017 | 2013 | 0.350 |
Why?
|
| Prevalence | 9 | 2019 | 910 | 0.330 |
Why?
|
| Pneumonia, Bacterial | 2 | 2007 | 31 | 0.320 |
Why?
|
| Saliva | 5 | 2022 | 36 | 0.320 |
Why?
|
| Tongue Neoplasms | 1 | 2008 | 5 | 0.320 |
Why?
|
| Dental Prophylaxis | 4 | 2012 | 4 | 0.320 |
Why?
|
| Lymphoma, B-Cell | 1 | 2008 | 12 | 0.310 |
Why?
|
| Radiotherapy, Intensity-Modulated | 5 | 2017 | 30 | 0.310 |
Why?
|
| Bacterial Infections | 2 | 2020 | 42 | 0.310 |
Why?
|
| Patient Care Planning | 1 | 2008 | 53 | 0.300 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2007 | 53 | 0.290 |
Why?
|
| Antirheumatic Agents | 2 | 2017 | 27 | 0.290 |
Why?
|
| Hemorrhage | 1 | 2007 | 94 | 0.290 |
Why?
|
| Double-Blind Method | 10 | 2009 | 507 | 0.280 |
Why?
|
| Aged | 13 | 2019 | 9572 | 0.280 |
Why?
|
| Registries | 2 | 2017 | 280 | 0.270 |
Why?
|
| Biological Products | 2 | 2017 | 66 | 0.270 |
Why?
|
| Osteonecrosis | 2 | 2019 | 16 | 0.260 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2004 | 2 | 0.260 |
Why?
|
| Biopsy | 5 | 2017 | 241 | 0.260 |
Why?
|
| Lupus Erythematosus, Cutaneous | 1 | 2005 | 13 | 0.250 |
Why?
|
| Treatment Outcome | 9 | 2017 | 3123 | 0.250 |
Why?
|
| Placebos | 6 | 2008 | 61 | 0.250 |
Why?
|
| United States | 8 | 2019 | 3685 | 0.250 |
Why?
|
| Follow-Up Studies | 8 | 2013 | 2121 | 0.250 |
Why?
|
| Alveolar Ridge Augmentation | 1 | 2004 | 2 | 0.250 |
Why?
|
| Immunity, Innate | 2 | 2016 | 64 | 0.250 |
Why?
|
| Specialties, Dental | 3 | 2013 | 3 | 0.240 |
Why?
|
| Thalidomide | 1 | 2004 | 29 | 0.240 |
Why?
|
| Respiration, Artificial | 1 | 2004 | 96 | 0.240 |
Why?
|
| Bone Transplantation | 1 | 2004 | 47 | 0.240 |
Why?
|
| Chronic Disease | 4 | 2014 | 371 | 0.240 |
Why?
|
| Ribonucleoproteins | 2 | 2016 | 15 | 0.240 |
Why?
|
| Evidence-Based Medicine | 6 | 2017 | 208 | 0.230 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2003 | 28 | 0.230 |
Why?
|
| Chromosomes, Human, X | 3 | 2017 | 12 | 0.230 |
Why?
|
| Severity of Illness Index | 6 | 2019 | 864 | 0.220 |
Why?
|
| Fatigue | 3 | 2017 | 70 | 0.220 |
Why?
|
| Blood Coagulation Tests | 1 | 2002 | 6 | 0.220 |
Why?
|
| Herpesviridae Infections | 2 | 2014 | 3 | 0.220 |
Why?
|
| Tooth Cervix | 1 | 2022 | 1 | 0.210 |
Why?
|
| Anemia, Aplastic | 1 | 2001 | 6 | 0.210 |
Why?
|
| Bacteria | 3 | 2019 | 45 | 0.200 |
Why?
|
| Sialadenitis | 1 | 2001 | 1 | 0.200 |
Why?
|
| Synovitis | 1 | 2001 | 6 | 0.200 |
Why?
|
| Malocclusion | 3 | 2001 | 5 | 0.200 |
Why?
|
| Pilocarpine | 3 | 2007 | 5 | 0.190 |
Why?
|
| Periodontitis | 3 | 2013 | 9 | 0.190 |
Why?
|
| Multiple Myeloma | 1 | 2021 | 15 | 0.190 |
Why?
|
| Epidemiologic Factors | 1 | 2020 | 2 | 0.190 |
Why?
|
| Sex Chromosome Aberrations | 2 | 2017 | 4 | 0.190 |
Why?
|
| Gene Expression Profiling | 2 | 2013 | 321 | 0.190 |
Why?
|
| Stem Cell Transplantation | 2 | 2021 | 203 | 0.190 |
Why?
|
| Papillomaviridae | 1 | 2020 | 17 | 0.190 |
Why?
|
| Lip | 1 | 2000 | 8 | 0.190 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 525 | 0.180 |
Why?
|
| Indians, North American | 1 | 2020 | 108 | 0.180 |
Why?
|
| Diarrhea | 2 | 2013 | 56 | 0.180 |
Why?
|
| Jaw Diseases | 1 | 2019 | 1 | 0.180 |
Why?
|
| Jaw | 1 | 2019 | 3 | 0.180 |
Why?
|
| Aged, 80 and over | 5 | 2016 | 3758 | 0.170 |
Why?
|
| Disease Susceptibility | 4 | 2019 | 53 | 0.170 |
Why?
|
| Bone Resorption | 1 | 1999 | 13 | 0.170 |
Why?
|
| Mandibular Condyle | 1 | 1999 | 6 | 0.170 |
Why?
|
| Trismus | 2 | 2010 | 4 | 0.170 |
Why?
|
| Amelogenesis Imperfecta | 1 | 1999 | 1 | 0.170 |
Why?
|
| Gingival Overgrowth | 1 | 1999 | 1 | 0.170 |
Why?
|
| Dermatomyositis | 1 | 1999 | 19 | 0.170 |
Why?
|
| Gingival Diseases | 4 | 2010 | 4 | 0.170 |
Why?
|
| Research | 1 | 2019 | 72 | 0.170 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2018 | 2 | 0.170 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2018 | 4 | 0.170 |
Why?
|
| Pilot Projects | 6 | 2010 | 486 | 0.170 |
Why?
|
| Sex Characteristics | 1 | 1999 | 167 | 0.160 |
Why?
|
| Heart Valve Diseases | 3 | 2012 | 25 | 0.160 |
Why?
|
| Survivors | 2 | 2018 | 148 | 0.160 |
Why?
|
| Chi-Square Distribution | 5 | 2012 | 293 | 0.160 |
Why?
|
| RNA, Messenger | 1 | 2000 | 520 | 0.160 |
Why?
|
| Drug Combinations | 2 | 2016 | 86 | 0.160 |
Why?
|
| Antiviral Agents | 2 | 2010 | 101 | 0.160 |
Why?
|
| Infection Control | 2 | 2010 | 21 | 0.160 |
Why?
|
| Anticoagulants | 2 | 2010 | 122 | 0.160 |
Why?
|
| Amoxicillin | 3 | 2008 | 3 | 0.160 |
Why?
|
| Mosaicism | 1 | 2017 | 1 | 0.160 |
Why?
|
| Young Adult | 6 | 2016 | 2423 | 0.160 |
Why?
|
| Reference Values | 2 | 2008 | 224 | 0.160 |
Why?
|
| 2',5'-Oligoadenylate Synthetase | 1 | 2017 | 1 | 0.150 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 35 | 0.150 |
Why?
|
| Interferon Type I | 1 | 2017 | 14 | 0.150 |
Why?
|
| Tooth Loss | 1 | 2017 | 7 | 0.150 |
Why?
|
| Child | 8 | 2013 | 2228 | 0.150 |
Why?
|
| Adolescent | 6 | 2016 | 3278 | 0.150 |
Why?
|
| Liver Diseases | 2 | 2008 | 62 | 0.150 |
Why?
|
| Radiography | 3 | 2008 | 355 | 0.150 |
Why?
|
| Radiation Injuries | 1 | 2017 | 68 | 0.150 |
Why?
|
| Periapical Diseases | 3 | 2009 | 3 | 0.150 |
Why?
|
| Anti-Infective Agents | 2 | 2016 | 43 | 0.140 |
Why?
|
| Quantitative Trait Loci | 1 | 2017 | 141 | 0.140 |
Why?
|
| Dental Restoration, Permanent | 2 | 2007 | 3 | 0.140 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2016 | 6 | 0.140 |
Why?
|
| Retroelements | 1 | 2016 | 3 | 0.140 |
Why?
|
| Klinefelter Syndrome | 1 | 2016 | 8 | 0.140 |
Why?
|
| Range of Motion, Articular | 2 | 2012 | 178 | 0.140 |
Why?
|
| Health Care Costs | 3 | 2016 | 108 | 0.140 |
Why?
|
| Clotrimazole | 1 | 2016 | 4 | 0.140 |
Why?
|
| Fluocinonide | 1 | 2016 | 11 | 0.140 |
Why?
|
| Autoimmunity | 1 | 2016 | 26 | 0.140 |
Why?
|
| Carbazoles | 1 | 2015 | 6 | 0.140 |
Why?
|
| Metoprolol | 1 | 2015 | 3 | 0.140 |
Why?
|
| Propanolamines | 1 | 2015 | 11 | 0.140 |
Why?
|
| Forecasting | 2 | 2007 | 133 | 0.130 |
Why?
|
| Dexamethasone | 1 | 2016 | 42 | 0.130 |
Why?
|
| Bone Marrow Transplantation | 2 | 2014 | 65 | 0.130 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2015 | 49 | 0.130 |
Why?
|
| Smoking | 2 | 2017 | 440 | 0.130 |
Why?
|
| Betamethasone | 1 | 2016 | 52 | 0.130 |
Why?
|
| Patient Admission | 1 | 2015 | 53 | 0.130 |
Why?
|
| Veterans | 1 | 2015 | 50 | 0.130 |
Why?
|
| Muscarinic Agonists | 2 | 2007 | 7 | 0.130 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 273 | 0.130 |
Why?
|
| Hospitals, Special | 1 | 2014 | 5 | 0.130 |
Why?
|
| Cell Line | 1 | 2016 | 455 | 0.130 |
Why?
|
| beta Karyopherins | 1 | 2014 | 7 | 0.130 |
Why?
|
| Interferon Regulatory Factors | 1 | 2014 | 12 | 0.130 |
Why?
|
| DNA | 1 | 2016 | 205 | 0.120 |
Why?
|
| Immunoglobulin G | 3 | 2004 | 105 | 0.120 |
Why?
|
| Statistics, Nonparametric | 5 | 2007 | 129 | 0.120 |
Why?
|
| Disease Management | 3 | 2019 | 114 | 0.120 |
Why?
|
| Rheumatology | 1 | 2014 | 7 | 0.120 |
Why?
|
| Analysis of Variance | 3 | 2012 | 455 | 0.120 |
Why?
|
| Dehydroepiandrosterone | 2 | 2004 | 10 | 0.120 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 116 | 0.120 |
Why?
|
| Child, Preschool | 5 | 2013 | 1171 | 0.120 |
Why?
|
| Europe | 1 | 2014 | 78 | 0.120 |
Why?
|
| Lactococcus lactis | 1 | 2013 | 1 | 0.120 |
Why?
|
| Adaptive Immunity | 1 | 2013 | 14 | 0.120 |
Why?
|
| Sucralfate | 1 | 2013 | 1 | 0.120 |
Why?
|
| Dental Occlusion, Traumatic | 1 | 2013 | 1 | 0.120 |
Why?
|
| Dry Socket | 1 | 2013 | 1 | 0.120 |
Why?
|
| Pericoronitis | 1 | 2013 | 1 | 0.120 |
Why?
|
| Pain, Referred | 1 | 2013 | 1 | 0.120 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 52 | 0.110 |
Why?
|
| Neck Pain | 1 | 2013 | 6 | 0.110 |
Why?
|
| Psychophysiologic Disorders | 1 | 2013 | 4 | 0.110 |
Why?
|
| Inflammation | 1 | 2017 | 510 | 0.110 |
Why?
|
| Education, Dental, Graduate | 1 | 2013 | 2 | 0.110 |
Why?
|
| Headache Disorders | 1 | 2013 | 17 | 0.110 |
Why?
|
| Tension-Type Headache | 1 | 2013 | 14 | 0.110 |
Why?
|
| Anesthetics | 1 | 2013 | 19 | 0.110 |
Why?
|
| Tissue Banks | 1 | 2013 | 16 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2013 | 72 | 0.110 |
Why?
|
| Gingivitis, Necrotizing Ulcerative | 1 | 2012 | 1 | 0.110 |
Why?
|
| Photochemotherapy | 1 | 2013 | 17 | 0.110 |
Why?
|
| Stomatitis, Aphthous | 1 | 2012 | 4 | 0.110 |
Why?
|
| Pemphigoid, Bullous | 1 | 2012 | 6 | 0.110 |
Why?
|
| Texas | 1 | 2012 | 36 | 0.110 |
Why?
|
| Connective Tissue Diseases | 1 | 2012 | 8 | 0.110 |
Why?
|
| Genetic Loci | 1 | 2013 | 147 | 0.110 |
Why?
|
| Florida | 1 | 2012 | 35 | 0.110 |
Why?
|
| Pemphigus | 1 | 2012 | 8 | 0.110 |
Why?
|
| African Americans | 1 | 2020 | 1375 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2020 | 1080 | 0.110 |
Why?
|
| Retinoids | 1 | 2013 | 41 | 0.110 |
Why?
|
| Brain Diseases | 1 | 2013 | 40 | 0.110 |
Why?
|
| Dental Plaque | 2 | 2009 | 2 | 0.110 |
Why?
|
| Physical Examination | 1 | 2013 | 82 | 0.110 |
Why?
|
| Laser Therapy | 1 | 2013 | 52 | 0.110 |
Why?
|
| Drug Costs | 1 | 2012 | 42 | 0.110 |
Why?
|
| Neuralgia | 1 | 2013 | 48 | 0.110 |
Why?
|
| Catheters, Indwelling | 2 | 2010 | 40 | 0.110 |
Why?
|
| DMF Index | 3 | 2017 | 6 | 0.110 |
Why?
|
| Areca | 1 | 2012 | 1 | 0.110 |
Why?
|
| Masticatory Muscles | 1 | 2012 | 1 | 0.110 |
Why?
|
| Myofunctional Therapy | 1 | 2012 | 1 | 0.110 |
Why?
|
| Transplantation, Autologous | 3 | 2021 | 78 | 0.110 |
Why?
|
| Carotenoids | 1 | 2012 | 9 | 0.110 |
Why?
|
| Virus Diseases | 3 | 2020 | 19 | 0.110 |
Why?
|
| Hepatitis | 1 | 2012 | 7 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2015 | 310 | 0.110 |
Why?
|
| Catheterization, Central Venous | 2 | 2010 | 60 | 0.100 |
Why?
|
| Analgesics | 1 | 2013 | 126 | 0.100 |
Why?
|
| Focal Infection, Dental | 1 | 2012 | 1 | 0.100 |
Why?
|
| Tooth Exfoliation | 1 | 2012 | 1 | 0.100 |
Why?
|
| Mental Disorders | 1 | 2013 | 111 | 0.100 |
Why?
|
| Case-Control Studies | 4 | 2017 | 861 | 0.100 |
Why?
|
| Cost of Illness | 2 | 2016 | 64 | 0.100 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2013 | 148 | 0.100 |
Why?
|
| Warfarin | 2 | 2010 | 30 | 0.100 |
Why?
|
| Retinol-Binding Proteins, Cellular | 1 | 2011 | 2 | 0.100 |
Why?
|
| Argininosuccinate Synthase | 1 | 2011 | 2 | 0.100 |
Why?
|
| Zinc Fingers | 1 | 2011 | 8 | 0.100 |
Why?
|
| Receptor, Notch1 | 1 | 2011 | 8 | 0.100 |
Why?
|
| Liver Cirrhosis | 1 | 2012 | 75 | 0.100 |
Why?
|
| Autoantigens | 1 | 2011 | 16 | 0.100 |
Why?
|
| Cation Transport Proteins | 1 | 2011 | 24 | 0.100 |
Why?
|
| Antioxidants | 1 | 2012 | 114 | 0.100 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 41 | 0.100 |
Why?
|
| Deglutition Disorders | 1 | 2011 | 50 | 0.100 |
Why?
|
| Schools, Dental | 1 | 2011 | 1 | 0.100 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 72 | 0.100 |
Why?
|
| Disease | 1 | 2011 | 4 | 0.100 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2011 | 35 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2011 | 71 | 0.100 |
Why?
|
| International Cooperation | 1 | 2011 | 25 | 0.100 |
Why?
|
| Periodontal Index | 2 | 2008 | 5 | 0.100 |
Why?
|
| RNA-Binding Proteins | 1 | 2011 | 68 | 0.100 |
Why?
|
| Genome, Human | 1 | 2011 | 129 | 0.100 |
Why?
|
| Cross-Sectional Studies | 4 | 2020 | 1380 | 0.100 |
Why?
|
| Carrier Proteins | 1 | 2011 | 131 | 0.090 |
Why?
|
| Fluorides | 3 | 2016 | 4 | 0.090 |
Why?
|
| Dysgeusia | 1 | 2010 | 1 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 141 | 0.090 |
Why?
|
| Cheilitis | 1 | 2010 | 1 | 0.090 |
Why?
|
| Lip Diseases | 1 | 2010 | 1 | 0.090 |
Why?
|
| Pharyngeal Diseases | 1 | 2010 | 8 | 0.090 |
Why?
|
| Diphosphonates | 1 | 2010 | 9 | 0.090 |
Why?
|
| Odds Ratio | 3 | 2017 | 448 | 0.090 |
Why?
|
| Bone Density Conservation Agents | 1 | 2010 | 20 | 0.090 |
Why?
|
| Continuity of Patient Care | 1 | 2011 | 64 | 0.090 |
Why?
|
| Patient Care Team | 1 | 2011 | 124 | 0.090 |
Why?
|
| Enoxaparin | 1 | 2010 | 19 | 0.090 |
Why?
|
| Heart Failure | 1 | 2015 | 575 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 2011 | 256 | 0.090 |
Why?
|
| Metagenomics | 2 | 2019 | 3 | 0.090 |
Why?
|
| Metagenome | 2 | 2019 | 5 | 0.090 |
Why?
|
| Myeloablative Agonists | 1 | 2009 | 2 | 0.090 |
Why?
|
| Infant | 3 | 2009 | 975 | 0.090 |
Why?
|
| Bleeding Time | 1 | 2008 | 1 | 0.080 |
Why?
|
| Hemostasis | 1 | 2008 | 5 | 0.080 |
Why?
|
| Chronic Periodontitis | 1 | 2008 | 2 | 0.080 |
Why?
|
| Platelet Aggregation | 1 | 2008 | 21 | 0.080 |
Why?
|
| North Carolina | 1 | 2012 | 1428 | 0.080 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2009 | 71 | 0.080 |
Why?
|
| Research Design | 2 | 2017 | 287 | 0.080 |
Why?
|
| Root Canal Therapy | 1 | 2008 | 1 | 0.080 |
Why?
|
| Blood Pressure | 2 | 2002 | 812 | 0.080 |
Why?
|
| Child, Hospitalized | 1 | 2007 | 8 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2008 | 101 | 0.080 |
Why?
|
| Blood Platelets | 1 | 2007 | 38 | 0.070 |
Why?
|
| Manuals as Topic | 1 | 2007 | 1 | 0.070 |
Why?
|
| Quinuclidines | 1 | 2007 | 3 | 0.070 |
Why?
|
| Pain Measurement | 2 | 2006 | 365 | 0.070 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2007 | 8 | 0.070 |
Why?
|
| Trisomy | 2 | 2017 | 8 | 0.070 |
Why?
|
| Respiratory System | 1 | 2007 | 12 | 0.070 |
Why?
|
| Pulpectomy | 1 | 2007 | 1 | 0.070 |
Why?
|
| Pulpotomy | 1 | 2007 | 1 | 0.070 |
Why?
|
| Hematologic Neoplasms | 3 | 2014 | 28 | 0.070 |
Why?
|
| Gene Dosage | 2 | 2017 | 34 | 0.070 |
Why?
|
| Renal Dialysis | 2 | 2012 | 265 | 0.070 |
Why?
|
| Thiophenes | 1 | 2007 | 21 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 725 | 0.070 |
Why?
|
| Thrombosis | 1 | 2007 | 60 | 0.070 |
Why?
|
| Hemostatics | 3 | 2013 | 12 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2004 | 247 | 0.070 |
Why?
|
| Alleles | 2 | 2017 | 251 | 0.070 |
Why?
|
| Delphi Technique | 2 | 2017 | 35 | 0.070 |
Why?
|
| Growth Substances | 1 | 2006 | 7 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2013 | 469 | 0.070 |
Why?
|
| Penicillin V | 1 | 2006 | 1 | 0.070 |
Why?
|
| Pulpitis | 1 | 2006 | 1 | 0.070 |
Why?
|
| Diffusion of Innovation | 1 | 2006 | 29 | 0.070 |
Why?
|
| Suppuration | 1 | 2006 | 6 | 0.070 |
Why?
|
| Bayes Theorem | 2 | 2017 | 69 | 0.070 |
Why?
|
| Edema | 1 | 2006 | 30 | 0.070 |
Why?
|
| Intubation, Intratracheal | 1 | 2007 | 71 | 0.070 |
Why?
|
| Information Dissemination | 1 | 2006 | 42 | 0.070 |
Why?
|
| Abscess | 1 | 2006 | 25 | 0.070 |
Why?
|
| Fever | 1 | 2006 | 56 | 0.070 |
Why?
|
| Self Care | 2 | 2017 | 137 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2006 | 111 | 0.070 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2005 | 5 | 0.070 |
Why?
|
| Genetic Association Studies | 2 | 2017 | 148 | 0.060 |
Why?
|
| Penicillins | 1 | 2004 | 8 | 0.060 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2004 | 13 | 0.060 |
Why?
|
| Radiography, Dental | 1 | 2004 | 2 | 0.060 |
Why?
|
| Infant, Low Birth Weight | 1 | 2004 | 9 | 0.060 |
Why?
|
| Maternal Exposure | 1 | 2004 | 10 | 0.060 |
Why?
|
| Intubation | 1 | 2004 | 8 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2008 | 200 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2004 | 45 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2004 | 51 | 0.060 |
Why?
|
| Mandible | 2 | 2021 | 38 | 0.060 |
Why?
|
| Critical Illness | 1 | 2004 | 88 | 0.060 |
Why?
|
| Blood Sedimentation | 2 | 2002 | 5 | 0.060 |
Why?
|
| Antibodies, Antinuclear | 2 | 2002 | 18 | 0.060 |
Why?
|
| Advance Care Planning | 1 | 2003 | 11 | 0.060 |
Why?
|
| Terminal Care | 1 | 2003 | 19 | 0.060 |
Why?
|
| Dihydrotestosterone | 1 | 2003 | 3 | 0.060 |
Why?
|
| Estrone | 1 | 2003 | 7 | 0.060 |
Why?
|
| Androstenedione | 1 | 2003 | 5 | 0.060 |
Why?
|
| Surgical Wound Infection | 1 | 2004 | 74 | 0.060 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2003 | 8 | 0.060 |
Why?
|
| Critical Care | 1 | 2004 | 115 | 0.060 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2003 | 14 | 0.060 |
Why?
|
| Testosterone | 1 | 2003 | 49 | 0.060 |
Why?
|
| Alveolar Bone Loss | 1 | 2002 | 3 | 0.060 |
Why?
|
| Logistic Models | 2 | 2002 | 729 | 0.060 |
Why?
|
| Tooth Mobility | 1 | 2002 | 1 | 0.060 |
Why?
|
| Saliva, Artificial | 1 | 2002 | 2 | 0.050 |
Why?
|
| Lung | 1 | 2004 | 237 | 0.050 |
Why?
|
| Choice Behavior | 1 | 2003 | 83 | 0.050 |
Why?
|
| Acupuncture Therapy | 1 | 2002 | 17 | 0.050 |
Why?
|
| Estradiol | 1 | 2003 | 118 | 0.050 |
Why?
|
| Keratoconjunctivitis Sicca | 1 | 2002 | 2 | 0.050 |
Why?
|
| Communication | 1 | 2003 | 123 | 0.050 |
Why?
|
| Intraoperative Complications | 1 | 2002 | 49 | 0.050 |
Why?
|
| Parotid Gland | 1 | 2022 | 6 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2002 | 174 | 0.050 |
Why?
|
| Gingival Hyperplasia | 1 | 2001 | 1 | 0.050 |
Why?
|
| Stomatitis, Herpetic | 1 | 2001 | 1 | 0.050 |
Why?
|
| Purpura | 1 | 2001 | 3 | 0.050 |
Why?
|
| Gingival Hemorrhage | 1 | 2001 | 3 | 0.050 |
Why?
|
| Oral Ulcer | 1 | 2001 | 5 | 0.050 |
Why?
|
| Fabry Disease | 1 | 2001 | 1 | 0.050 |
Why?
|
| Paranasal Sinus Diseases | 1 | 2001 | 3 | 0.050 |
Why?
|
| Cyclosporine | 1 | 2001 | 34 | 0.050 |
Why?
|
| Patient Selection | 2 | 2017 | 257 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2001 | 141 | 0.050 |
Why?
|
| Neutropenia | 2 | 2012 | 23 | 0.050 |
Why?
|
| Melphalan | 1 | 2021 | 4 | 0.050 |
Why?
|
| Hypertension | 2 | 2011 | 916 | 0.050 |
Why?
|
| Endocrine System Diseases | 1 | 2020 | 4 | 0.050 |
Why?
|
| Dental Scaling | 2 | 2011 | 2 | 0.050 |
Why?
|
| Root Planing | 2 | 2011 | 2 | 0.050 |
Why?
|
| Alveoloplasty | 2 | 2011 | 3 | 0.050 |
Why?
|
| Oklahoma | 1 | 2020 | 2 | 0.050 |
Why?
|
| Mouthwashes | 2 | 2013 | 3 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 533 | 0.050 |
Why?
|
| Phosphorus Radioisotopes | 1 | 2000 | 4 | 0.050 |
Why?
|
| Blotting, Southern | 1 | 2000 | 21 | 0.050 |
Why?
|
| Salivary Ducts | 1 | 2000 | 2 | 0.050 |
Why?
|
| DNA Probes | 1 | 2000 | 17 | 0.050 |
Why?
|
| Skin | 1 | 2002 | 205 | 0.050 |
Why?
|
| Dissection | 1 | 2000 | 16 | 0.050 |
Why?
|
| Malnutrition | 1 | 2020 | 17 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2000 | 35 | 0.050 |
Why?
|
| Interleukin-1 | 1 | 2000 | 33 | 0.050 |
Why?
|
| Interleukin-4 | 1 | 2000 | 21 | 0.050 |
Why?
|
| Hematologic Diseases | 1 | 2020 | 23 | 0.050 |
Why?
|
| Nucleotides | 1 | 2020 | 16 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2000 | 51 | 0.050 |
Why?
|
| Microsurgery | 1 | 2000 | 19 | 0.050 |
Why?
|
| Interleukin-10 | 1 | 2000 | 30 | 0.050 |
Why?
|
| Actins | 1 | 2000 | 52 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2021 | 150 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2002 | 727 | 0.050 |
Why?
|
| Nervous System Diseases | 1 | 2020 | 37 | 0.050 |
Why?
|
| Dental Plaque Index | 2 | 2010 | 4 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 1 | 2000 | 66 | 0.050 |
Why?
|
| Gingivitis | 2 | 2010 | 5 | 0.050 |
Why?
|
| Fungi | 1 | 2019 | 5 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2019 | 15 | 0.040 |
Why?
|
| Serologic Tests | 1 | 1999 | 10 | 0.040 |
Why?
|
| Gelatin Sponge, Absorbable | 2 | 2010 | 5 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2000 | 248 | 0.040 |
Why?
|
| Thrombin | 2 | 2010 | 15 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2000 | 88 | 0.040 |
Why?
|
| Telomere | 1 | 2019 | 10 | 0.040 |
Why?
|
| Salivary Glands | 1 | 2019 | 14 | 0.040 |
Why?
|
| Sutures | 2 | 2010 | 19 | 0.040 |
Why?
|
| Systems Biology | 1 | 2019 | 9 | 0.040 |
Why?
|
| Denmark | 1 | 2019 | 3 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2007 | 1055 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2000 | 225 | 0.040 |
Why?
|
| Osteotomy, Le Fort | 1 | 1999 | 3 | 0.040 |
Why?
|
| Porphyromonas gingivalis | 1 | 1999 | 1 | 0.040 |
Why?
|
| Prevotella intermedia | 1 | 1999 | 1 | 0.040 |
Why?
|
| Campylobacter | 1 | 1999 | 2 | 0.040 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 64 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 337 | 0.040 |
Why?
|
| Oral Hygiene Index | 2 | 2009 | 2 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2019 | 88 | 0.040 |
Why?
|
| Xerophthalmia | 2 | 2013 | 2 | 0.040 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2018 | 31 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2018 | 47 | 0.040 |
Why?
|
| Dysostoses | 1 | 1998 | 1 | 0.040 |
Why?
|
| Osteopetrosis | 1 | 1998 | 2 | 0.040 |
Why?
|
| Dwarfism | 1 | 1998 | 3 | 0.040 |
Why?
|
| Facial Bones | 1 | 1998 | 10 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 438 | 0.040 |
Why?
|
| Turner Syndrome | 1 | 2017 | 2 | 0.040 |
Why?
|
| Acute Disease | 2 | 2009 | 239 | 0.040 |
Why?
|
| Semantics | 1 | 2017 | 11 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2018 | 140 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2017 | 35 | 0.040 |
Why?
|
| Viridans Streptococci | 2 | 2009 | 4 | 0.040 |
Why?
|
| Alternative Splicing | 1 | 2017 | 28 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2008 | 24 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2017 | 50 | 0.040 |
Why?
|
| Prognosis | 1 | 2021 | 1369 | 0.040 |
Why?
|
| Decision Trees | 1 | 2017 | 23 | 0.040 |
Why?
|
| Consensus | 1 | 2017 | 70 | 0.040 |
Why?
|
| Radiation Dosage | 1 | 2017 | 72 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2017 | 42 | 0.040 |
Why?
|
| Cariostatic Agents | 1 | 2016 | 3 | 0.040 |
Why?
|
| Hydroxychloroquine | 1 | 2016 | 9 | 0.040 |
Why?
|
| Chromosomes, Human, Y | 1 | 2016 | 2 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 38 | 0.040 |
Why?
|
| Sarcoidosis | 1 | 2016 | 27 | 0.030 |
Why?
|
| HIV Infections | 2 | 2014 | 371 | 0.030 |
Why?
|
| Secretory Rate | 2 | 2008 | 2 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2016 | 225 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 188 | 0.030 |
Why?
|
| Hospitals, Veterans | 1 | 2015 | 33 | 0.030 |
Why?
|
| Pain | 1 | 2017 | 283 | 0.030 |
Why?
|
| Alphaherpesvirinae | 1 | 2014 | 1 | 0.030 |
Why?
|
| Betaherpesvirinae | 1 | 2014 | 1 | 0.030 |
Why?
|
| Gammaherpesvirinae | 1 | 2014 | 1 | 0.030 |
Why?
|
| Coxsackievirus Infections | 1 | 2014 | 2 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 483 | 0.030 |
Why?
|
| Alphapapillomavirus | 1 | 2014 | 9 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2015 | 113 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2005 | 162 | 0.030 |
Why?
|
| Genotype | 1 | 2016 | 735 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2014 | 95 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2014 | 61 | 0.030 |
Why?
|
| Haplotypes | 1 | 2014 | 220 | 0.030 |
Why?
|
| Exercise Therapy | 1 | 2016 | 237 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 143 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2014 | 115 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2013 | 10 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 213 | 0.030 |
Why?
|
| Anti-Ulcer Agents | 1 | 2013 | 3 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 840 | 0.030 |
Why?
|
| Gingiva | 1 | 2013 | 1 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2013 | 10 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2013 | 10 | 0.030 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2013 | 8 | 0.030 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2013 | 18 | 0.030 |
Why?
|
| Tongue | 1 | 2013 | 13 | 0.030 |
Why?
|
| Accreditation | 1 | 2013 | 14 | 0.030 |
Why?
|
| Curriculum | 1 | 2015 | 198 | 0.030 |
Why?
|
| Keratinocytes | 1 | 2013 | 26 | 0.030 |
Why?
|
| Dental Offices | 1 | 2012 | 1 | 0.030 |
Why?
|
| Breast Implants | 1 | 2012 | 2 | 0.030 |
Why?
|
| Fees, Pharmaceutical | 1 | 2012 | 2 | 0.030 |
Why?
|
| Hemostasis, Surgical | 1 | 2013 | 13 | 0.030 |
Why?
|
| Joint Prosthesis | 1 | 2012 | 5 | 0.030 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2012 | 7 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2013 | 63 | 0.030 |
Why?
|
| Endocarditis | 1 | 2012 | 11 | 0.030 |
Why?
|
| Defibrillators, Implantable | 1 | 2012 | 17 | 0.030 |
Why?
|
| Heart Transplantation | 1 | 2012 | 26 | 0.030 |
Why?
|
| Pacemaker, Artificial | 1 | 2012 | 17 | 0.030 |
Why?
|
| Heart Defects, Congenital | 1 | 2012 | 28 | 0.030 |
Why?
|
| DNA Damage | 1 | 2013 | 88 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2013 | 103 | 0.030 |
Why?
|
| RNA | 1 | 2013 | 88 | 0.030 |
Why?
|
| Office Visits | 1 | 2012 | 71 | 0.030 |
Why?
|
| Animals | 2 | 2019 | 7328 | 0.030 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2012 | 79 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 282 | 0.030 |
Why?
|
| Heart Valve Prosthesis | 1 | 2012 | 53 | 0.030 |
Why?
|
| Hepatitis B, Chronic | 1 | 2012 | 6 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2013 | 269 | 0.030 |
Why?
|
| Tooth, Deciduous | 1 | 2012 | 3 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2013 | 251 | 0.030 |
Why?
|
| Cephalosporins | 1 | 2012 | 7 | 0.030 |
Why?
|
| Causality | 1 | 2011 | 39 | 0.030 |
Why?
|
| Clindamycin | 1 | 2012 | 18 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2012 | 73 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2013 | 180 | 0.030 |
Why?
|
| Subgingival Curettage | 1 | 2011 | 1 | 0.030 |
Why?
|
| Dental Implantation, Endosseous | 1 | 2011 | 4 | 0.030 |
Why?
|
| Hepatitis C, Chronic | 1 | 2012 | 77 | 0.030 |
Why?
|
| Methotrexate | 1 | 2012 | 60 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2012 | 180 | 0.020 |
Why?
|
| Anxiety Disorders | 1 | 2011 | 61 | 0.020 |
Why?
|
| Zinc Sulfate | 1 | 2010 | 1 | 0.020 |
Why?
|
| Amifostine | 1 | 2010 | 2 | 0.020 |
Why?
|
| Survival Rate | 1 | 2013 | 796 | 0.020 |
Why?
|
| Oropharynx | 1 | 2010 | 7 | 0.020 |
Why?
|
| Herpes Simplex | 1 | 2010 | 12 | 0.020 |
Why?
|
| Staphylococcaceae | 1 | 2010 | 1 | 0.020 |
Why?
|
| Streptococcus mitis | 1 | 2010 | 2 | 0.020 |
Why?
|
| Streptococcus | 1 | 2010 | 7 | 0.020 |
Why?
|
| Evidence-Based Emergency Medicine | 1 | 2010 | 2 | 0.020 |
Why?
|
| Molecular Biology | 1 | 2010 | 7 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2010 | 25 | 0.020 |
Why?
|
| Hemostatic Techniques | 1 | 2010 | 7 | 0.020 |
Why?
|
| Vitamin K | 1 | 2010 | 9 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2010 | 55 | 0.020 |
Why?
|
| Plasma | 1 | 2010 | 15 | 0.020 |
Why?
|
| Antifibrinolytic Agents | 1 | 2010 | 16 | 0.020 |
Why?
|
| Comorbidity | 1 | 2011 | 548 | 0.020 |
Why?
|
| Streptococcus pneumoniae | 1 | 2010 | 40 | 0.020 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2010 | 40 | 0.020 |
Why?
|
| Dental Calculus | 1 | 2009 | 1 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2010 | 56 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2010 | 49 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2010 | 62 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 796 | 0.020 |
Why?
|
| Coagulants | 1 | 2009 | 2 | 0.020 |
Why?
|
| Dental Implants | 1 | 2009 | 6 | 0.020 |
Why?
|
| Neutrophils | 1 | 2010 | 102 | 0.020 |
Why?
|
| Medical History Taking | 1 | 2009 | 32 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2009 | 64 | 0.020 |
Why?
|
| Ion Transport | 1 | 2008 | 5 | 0.020 |
Why?
|
| Body Water | 1 | 2008 | 8 | 0.020 |
Why?
|
| Absorption | 1 | 2008 | 15 | 0.020 |
Why?
|
| Water-Electrolyte Balance | 1 | 2008 | 14 | 0.020 |
Why?
|
| Water | 1 | 2008 | 52 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2011 | 246 | 0.020 |
Why?
|
| Interleukins | 1 | 2008 | 17 | 0.020 |
Why?
|
| Depression | 1 | 2011 | 386 | 0.020 |
Why?
|
| Review Literature as Topic | 1 | 2007 | 7 | 0.020 |
Why?
|
| Transplants | 1 | 2007 | 22 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2009 | 158 | 0.020 |
Why?
|
| Ascites | 1 | 2007 | 13 | 0.020 |
Why?
|
| Phylogeny | 1 | 2007 | 58 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2007 | 43 | 0.020 |
Why?
|
| Species Specificity | 1 | 2007 | 85 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2007 | 67 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2007 | 46 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2011 | 674 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2007 | 69 | 0.020 |
Why?
|
| Agranulocytosis | 1 | 2006 | 1 | 0.020 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 2006 | 1 | 0.020 |
Why?
|
| Gram-Positive Bacteria | 1 | 2006 | 2 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2006 | 10 | 0.020 |
Why?
|
| Gram-Negative Bacteria | 1 | 2006 | 7 | 0.020 |
Why?
|
| Age Factors | 1 | 2009 | 1120 | 0.020 |
Why?
|
| Primary Prevention | 1 | 2006 | 51 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 2006 | 48 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2007 | 171 | 0.020 |
Why?
|
| Stents | 1 | 2007 | 171 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 197 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2007 | 231 | 0.020 |
Why?
|
| Radiation Protection | 1 | 2004 | 7 | 0.020 |
Why?
|
| Thyroid Gland | 1 | 2004 | 13 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2004 | 33 | 0.020 |
Why?
|
| Nasal Cavity | 1 | 2004 | 5 | 0.020 |
Why?
|
| Streptococcal Infections | 1 | 2004 | 20 | 0.020 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2004 | 47 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 299 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 2007 | 251 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 97 | 0.010 |
Why?
|
| Trachea | 1 | 2004 | 55 | 0.010 |
Why?
|
| Connecticut | 1 | 2003 | 2 | 0.010 |
Why?
|
| Nursing Methodology Research | 1 | 2003 | 5 | 0.010 |
Why?
|
| Attitude to Death | 1 | 2003 | 2 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 673 | 0.010 |
Why?
|
| Professional-Patient Relations | 1 | 2003 | 21 | 0.010 |
Why?
|
| Risk | 1 | 2004 | 292 | 0.010 |
Why?
|
| Emergency Medicine | 1 | 2004 | 117 | 0.010 |
Why?
|
| Educational Status | 1 | 2003 | 165 | 0.010 |
Why?
|
| Bacteria, Aerobic | 1 | 2002 | 1 | 0.010 |
Why?
|
| Bacterial Typing Techniques | 1 | 2002 | 9 | 0.010 |
Why?
|
| Bacteria, Anaerobic | 1 | 2002 | 3 | 0.010 |
Why?
|
| Family | 1 | 2003 | 105 | 0.010 |
Why?
|
| Immunoglobulin A, Secretory | 1 | 2002 | 3 | 0.010 |
Why?
|
| Rheumatoid Factor | 1 | 2002 | 4 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 1389 | 0.010 |
Why?
|
| Infection Control, Dental | 1 | 2002 | 1 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 2002 | 16 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 641 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2004 | 604 | 0.010 |
Why?
|
| Systole | 1 | 2002 | 88 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 983 | 0.010 |
Why?
|
| Diastole | 1 | 2002 | 91 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2002 | 107 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2003 | 148 | 0.010 |
Why?
|
| Jaw, Edentulous | 1 | 2001 | 2 | 0.010 |
Why?
|
| Angiokeratoma | 1 | 2001 | 2 | 0.010 |
Why?
|
| Prognathism | 1 | 2001 | 4 | 0.010 |
Why?
|
| Maxillary Sinus | 1 | 2001 | 6 | 0.010 |
Why?
|
| Cephalometry | 1 | 2001 | 18 | 0.010 |
Why?
|
| Cysts | 1 | 2001 | 16 | 0.010 |
Why?
|
| Pregnancy | 1 | 2004 | 823 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2007 | 1327 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2003 | 328 | 0.010 |
Why?
|
| Mice | 1 | 2006 | 2383 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2001 | 206 | 0.010 |
Why?
|
| Micrognathism | 1 | 1998 | 2 | 0.010 |
Why?
|
| Palate | 1 | 1998 | 5 | 0.010 |
Why?
|
| Maxilla | 1 | 1998 | 9 | 0.010 |
Why?
|